DiaMonTech AG
DiaMonTech AG develops a non-invasive, painless blood glucose monitor called DMT-Pocket using photothermal spectroscopy technology.
Classification
Profile
Funding
Funding details not yet available.
Non-invasive, painless, and precise blood glucose measurement via the DMT-Pocket device using photothermal spectroscopy.
Individuals requiring frequent blood glucose monitoring, specifically those seeking pain-free alternatives to traditional finger-prick tests.
Information insufficient to determine the specific pricing strategy, though they are an innovative tech startup.
Information insufficient regarding specific sales motions or distribution channels.
Co-financed by the European Regional Development Fund (EFRE) for project implementation.
R&D for implementing photothermal spectroscopy into a mobile medical product; team operations based in Berlin.
Proprietary photothermal spectroscopy scientific method; international team based in Berlin.
Developing the DMT-Pocket mobile medical product and implementing the photothermal spectroscopy method.
Information insufficient to determine the specific acquisition or retention model.
Competes in the non-invasive glucose monitoring space; differentiates via photothermal spectroscopy technology for painless measurement.
Pain and inconvenience of traditional finger-prick blood glucose tests; need for precise, non-invasive monitoring solutions.
- Expand public-facing evidence - publish independent third-party study results and patient testimonials to boost consumer trust and accele
Are you planning a full market launch this year, or are you still in pilot/clinical phases? · Which geographies are top priority for regulatory approval (e.g., US, Japan, China)? · Do you have an existing pricing model for the SaaS analytics platform, or is it still under development?
EFRE funding supports the high R&D costs required to translate the key resource into the core value proposition.
- Strong IP portfolio (100+ patents) and CE certification provide tangible barriers to entry, reinforcing the company’s technical credibili
No investors recorded yet.